PART I FINANCIAL INFORMATION

Item 1.	Financial Statements

	Balance sheets - March 31, 2007 (unaudited) and
	December 31, 2006	3

	Statements of Operations - Three Months Ended
	March 31, 2007 and 2006 as restated (unaudited)	4

	Statements of Cash Flows- Three Months Ended
	March 31, 2007 and 2006 as restated (unaudited)	5

	Notes to Financial Statements (unaudited)	6

Item 2.	Management's Discussion and Analysis of Financial Condition
	And Plan of Operation	15

Item 3.	Controls and Procedures	18


PART II OTHER INFORMATION

Item 1.	Legal Proceedings	18

Item 2.	Changes in Securities	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Submission of Matters to a Vote of Security Holders	18

Item 5.	Other Information	18

Item 6.	Exhibits and Reports on Form 8-K	19

Signatures.		20

Certifications		21

PART I FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

STATSURE DIAGNOSTIC SYSTEMS, INC.

BALANCE SHEETS

	March 31, 2007			December 31, 2006
	(Unaudited)

ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	24,837		$	109,332
Accounts receivable, net of allowance for doubtful accounts		107,664			176,135
Inventories		43,937			40,241
Prepaid expenses		8,507			6,857

Total current assets		184,945			332,565

Property and equipment, net of accumulated depreciation of $561,280 (2007) and $557,613 (2006)		38,482			42,149

OTHER ASSETS:
Patents and trademarks, net of accumulated amortization of $152,019 (2007) and $148,428 (2006)		110,627			108,108
Deferred costs, less accumulated amortization of $460,562(2007) and $455,503 (2006)		11,438			16,497
Deposits		14,350			14,350

Total other assets		136,415			138,955

TOTAL ASSETS	$	359,842		$	513,669

LIABILITIES AND SHAREHOLDERS’ DEFICIT

CURRENT LIABILITIES:
Note payable - shareholders	$	156,313		$	240,000
Debentures payable-net of discount		106,878			70,568
Accounts payable		129,838			100,758
Customer advances		—			31,792
Accrued expenses		505,651			360,665
Accrued payroll expense to officers		127,499			127,499
Payroll and payroll taxes payable		11,300			11,300
Dividends payable in stock to preferred stockholders		49,500			49,500

Total current liabilities		1,086,979			992,082

LONG-TERM DEBT
Deferred rent payable		6,352			6,745
Note payable - shareholder		1,516,504			1,361,504
Derivative instrument		1,842,517			3,238,778

TOTAL LIABILITIES		4,452,352			5,599,109

COMMITMENTS AND CONTINGENCIES

Series 2006-A Convertible Preferred Stock: 2,500shares authorized, $.001 par value, 2,150 issued and outstanding		2			2
SHAREHOLDERS’ DEFICIT:
Series 1998-B Convertible Preferred Stock: 1,645 shares authorized, none issued and outstanding		—			—
Common stock, $.001 par value, 50,000,000 shares authorized, issued and outstanding: 37,294,219 (2007) and 37,213,151 (2006)		37,294			37,213
Additional paid-in capital		46,765,336			46,643,371
Accumulated deficit		(50,895,142	)		(51,766,026	)

TOTAL SHAREHOLDERS’ DEFICIT		(4,092,512	)		(5,085,442	)

TOTAL LIABILITIES AND SHAREHLDERS’ DEFICIT	$	359,842		$	513,669

The accompanying notes are an integral part of these statements.

STATSURE DIAGNOSTIC SYSTEMS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended March 31,
	2007			2006

REVENUES:
Product Sales	$	142,862		$	213,059
Other		10,986			—

Total revenues		153,848			213,059

COSTS OF PRODUCTS SOLD		21,729			46,390

Gross profit		132,119			166,669

OPERATING EXPENSES:
Research and development expenses		21,048			69,149
Selling, general and administrative expense		431,104			661,340

Total costs and expenses		452,152			730,489

Loss from operations		(320,033	)		(563,820	)

OTHER INCOME (EXPENSES):

Interest expense - net		(55,034	)		(123,962	)
Interest expense on beneficial conversion feature		(36,310	)		(117,612	)
Derivative income		1,396,261			—
Penalties		(64,500	)		—

Total other income (expenses):		1,240,417			(241,574	)
		920,384			(805,394	)
Net Income (Loss) before provision for income taxes

Provision for income taxes		—			—

NET INCOME (LOSS)		920,384			(805,394	)

Dividends - Preferred stock series 2006-A		49,500			—

NET INCOME (LOSS) TO COMMON SHAREHOLDERS	$	870,884		$	(805,394	)

BASIC INCOME (LOSS) PER SHARE	$	0.02		$	(0.03	)

WEIGHTED AVERAGE NUMBER OF SHARES USED IN BASIC PER SHARE CALCULATION		37,262,277			32,192,408
DILUTED INCOME (LOSS) PER SHARE	$	0.02		$	(0.03	)

WEIGHTED AVERAGE NUMBER OF SHARES USED IN DILUTED PER SHARE CALCULATION		45,988,736			32,192,408

The accompanying notes are an integral part of these statements.

STATSURE DIAGNOSTIC SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
	2007			2006
OPERATING ACTIVITIES:
Net income (loss)	$	920,384		$	(805,394	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		7,258			9,072
Amortization of deferred costs		5,059			56,730
Options granted to non-employee		11,622			11,621
Beneficial conversion feature of convertible debentures		36,310			117,612
Stock issued for consulting services		—			112,000
Options granted to employees as compensation		60,924			164,614
Mark-to-Market gain on derivative instruments		(1,396,261	)		—
Changes in assets and liabilities:
Accounts receivable		68,471			65,791
Inventories		(3,696	)		(26,033	)
Prepaid expenses		(1,650	)		4,608
Accounts payable, accrued payroll expense to officers and accrued expenses		142,274			201,109
Deferred rent		(393	)		—

Net cash used in operating activities		(149,698	)		(88,270	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of patents and trademarks		(6,110	)		(34,814	)

Net cash used in investing activities		(6,110	)		(34,814	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from shareholder loans		155,000			146,222
Repayments of shareholder loans		(83,687	)		(104,852	)
Proceeds from issuance of common stock		—			15,000

Net cash provided by financing activities		71,313			56,370

NET DECREASE IN CASH AND CASH EQUIVALENTS		(84,495	)		(66,714	)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		109,332			76,321

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	24,837		$	9,607

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	$	2,441		$	—

SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES:
Common stock issued in lieu of cash dividend payments	$	49,500		$	—
Reclassification of accrued interest to loan principal	$	—		$	239,404

The accompanying notes are an integral part of these statements.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

1. Description of Business

StatSure Diagnostic Systems, Inc., a Delaware corporation ("the Company"), is primarily engaged in the development, manufacture and marketing of rapid in-vitro assays for use in the detection of infectious diseases and other conditions, and medical specimen collection devices. The Company is currently marketing its medical specimen collection devices both in the U.S. and overseas.

On September 29, 2006, the Company announced it had signed several agreements relating to its patented barrel technology for use in screening antibodies to HIV (Human Immunodeficiency Virus, the virus that causes AIDS). As part of a three-way alliance with Inverness Medical Innovations (AMEX:IMA) Chembio Diagnostics (CEMI.OB) (“Chembio”), and the Company signed a worldwide, exclusive distribution deal for a rapid, point-of-care HIV test with Inverness. In a two-way deal with Chembio, the Company granted an exclusive license to Chembio solely to manufacture their recently FDA approved HIV barrel product for Inverness. This product will be marketed under the IMA brand. In this two-way agreement (“Joint HIV Barrel Commercialization Agreement”), a long- term strategic “partnership” was established, wherein both companies equally split the margin dollars of the HIV barrel product once the actual cost of manufacturing is reimbursed.

At the beginning of business on January 24, 2006, the Company effected a name change from Saliva Diagnostic Systems, Inc. to StatSure Diagnostic Systems, Inc.

2. Substantial Doubt Regarding Ability To Continue As A Going Concern

Since July 1990, the Company has been engaged almost exclusively in research and development activities focused on developing proprietary saliva based collection devices and rapid assays for infectious diseases. Other than sales of the Company's collection devices, the Company has not yet commenced any significant product commercialization. The Company incurred significant operating losses since its inception, resulting in an accumulated deficit of $50,895,142 at March 31, 2007. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. In addition, the Company is in default on certain debt obligations. Despite the Company's financings in 2006 (See Notes 5, 6, and 7), substantial additional financing will be required in future periods.

The Company's capital requirements have been and will continue to be significant. The Company's capital base is smaller than that of many of its competitors, and there can be no assurance that the Company's cash resources will be able to sustain its business. The Company is dependent upon its effort to raise capital to finance its future operations, including the cost of development, manufacturing and marketing of its products, to conduct clinical trials and submissions for FDA approval of its products and to continue the design and development of its new products. Marketing, manufacturing and clinical testing may require capital resources substantially greater than the resources available to the Company. The Company intends to continue to seek public or private placement of its equity securities in order to provide the funds necessary to meet its obligations. In addition, Management believes that the agreements it entered into in September 2006 (See Note 1), will enable the Company to increase its revenues significantly in the second half of this fiscal year. The Company's future capital needs will depend upon numerous factors, including the progress of the approval for sale of the Company's products in various countries, including the United States, the extent and timing of the acceptance of the Company's products, the cost of marketing and manufacturing activities and the amount of revenues generated from operations, none of which can be predicted with certainty. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's significant operating losses and significant capital requirements, however, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

3. Summary of Significant Accounting Policies

Basis of Presentation:

The accompanying unaudited financial statements as of, and for the three month periods ended March 31, 2007 and 2006, have been prepared in conformity with accounting principles generally accepted in the United States of America. The financial information as of December 31, 2006, is derived from StatSure Diagnostic Systems, Inc. (the "Company") financial statements included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006. Certain information or footnote disclosures in this filing that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim filings. In the opinion of management, the accompanying financial statements include all adjustments necessary (which are of a normal and recurring nature) for a fair presentation of the results of the interim periods presented. The accompanying financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2006, as included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006. Operating results for the three month period ended March 31, 2007 are not necessarily indicative of the results that may be expected for the entire year ending December 31, 2007, or any other portion thereof.

Recent Accounting Pronouncement:

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (SFAS No. 159). SFAS No. 159 permits entities to choose to measure, on an item-by-item basis, specified financial instruments and certain other items at fair value. Unrealized gains and losses on items for which the fair value has been elected are required to be reported in earnings at each reporting date. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, the provisions of which are required to be applied prospectively. The Company expects to adopt SFAS No. 159 in the first quarter of fiscal 2008.

Earnings (Loss) Per Common Share

The Company utilizes the guidance provided by Statement of Financial Accounting Standards No. 128, “Earnings per Share” (SFAS 128). Earnings Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) reflects the potential dilution from the exercise or conversion of other securities into common stock, but only if dilutive. The fully diluted earnings per share of $.02 for the three months ended March 31, 2007 is the same as basic earnings per share. This is due to the securieties presented on a common stock equivalent basis and outstanding at March 31, 2007 have been excluded from the per share computation as the add back of the change in fair value of the derivative income effect would be anti-dilutive. The diluted loss per share of $(.02) for the three months ended March 31, 2006 is the same as the basic loss per share. Such securities presented on a common stock equivalent basis and outstanding at March 31, 2006 have been excluded from the per share computation because they are antidilutive.

4. Geographic Area Information

Under the disclosure requirements of SFAS No. 131, “Segment Disclosures and Related Information,” we operate within one segment. Our products are sold principally in the United States and Europe. Segmentation of identifiable assets is not applicable since all of our revenues outside the United States are export sales.

The following table represents total product sales revenue by geographic area:

	Three months ended March 31,
	2007		2006

United States	$	52,642	$	51,064
United Kingdom		70,870		158,936
Africa		-		588
Others		19,350		2,471
	$	142,862	$	213,059

5. Debentures Payable

On January 19, 2005, the Company's board of directors authorized the issuance and sale of up to three million dollars of convertible debentures. These debentures mature March 31, 2009, and carry an interest rate of 9% per year and are convertible into common stock at the lower of 66.6% of the valuation of the Company's next raise of equity or $1 per share. In accordance with EITF Issue 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios", the Company had evaluated that the convertible debt had a beneficial conversion feature as the conversion price was less than the fair value of the Company's common stock on the measurement date. Under paragraph 6 of EITF 98-5, the discount related to the beneficial conversion feature would be calculated based on its intrinsic value which was $2,614,400, and is limited to the amount of the proceeds of $1,510,000 allocated to the convertible debt instrument. Accordingly, the beneficial conversion feature is being amortized using the interest method of accounting, resulting in a charge to interest expense of $36,310 for the three months ended March 31, 2007. The Company had sold an aggregate of $1,510,000 in convertible debentures. In September 2005, a debenture in the amount of $60,000 was converted into 60,000 shares of common stock. In May 2006, the Company issued 796,056 and 701,754 shares of common stock at $0.90 and $0.57 per share, respectively, for the induced conversion of $1,109,607 in convertible debentures including interest of $109,608. The debenture holders accepted these shares as full consideration for the outstanding convertible debentures. The Company recognized an additional expense of $403,872 because of the induced conversion to the debenture holders pursuant to the accounting requirements of SFAS No. 84, Induced Conversions of Convertible Debt. The original terms of the debentures called for them to be converted at $1.00 per share. The Company induced the debenture holders to convert at $0.90 and $0.57 per share.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

The Company is in default to the debenture holders for not making payments on a timely basis. As a result, in accordance with the debenture agreements, these debentures became payable on demand unless the default is waived by the investors. The amount of debentures at March 31, 2007 of $337,500 plus accrued interest of $23,476 has therefore been reflected as a current liability. The Company has not received any notice of default from any of the holders of the outstanding debentures.

Debentures payable-net of discount in the amount of $106,878, is the net of gross amount of debenture payables of $337,500 reduced by unamortized debt discount of $230,622, and is shown on the balance sheet as a current liability.

6. Financing From Shareholders

Per a promissory note dated February 2003, Jules Nordlicht, a shareholder, agreed to advance in total or in installments, up to the amount of $1,000,000 to the Company. In November 2003 and August 2004, agreements were executed with this shareholder to cause additional advances in total or in installments up to the amount of $2,500,000 to advance the process of the FDA approval. In consideration for the financing, the Company agreed to repay such borrowed funds with accrued interest at 12% per annum and the shareholder reserved the right to demand payment in full or in part at anytime after December 31, 2006. On May 8, 2006 the shareholder agreed to extend the maturity date to December 31, 2008 provided that (i) a partial payment of $350,000 will be made by the Company on or prior to July 31, 2006 and (ii) accrued interest will be paid quarterly thereafter, commencing September 30, 2006. The agreement was amended on September 4, 2006 so that the Company need no longer pay the quarterly accrued interest but an amount of $60,000 quarterly as a principal reduction. If the Company should default in these payments, the promissory note reverts to the original maturity date of December 31, 2006. As of March 31, 2007, the loan balance to this shareholder aggregated $1,672,817. An additional amount of $47,544 of interest on this note has been accrued during 2007 and remains owed as of March 31, 2007. The lender has filed a Uniform Commercial Code (UCC) Lien on the Company's equipment and patents as security for this loan. Minimum payments due under the promissory note as of March 31, 2007 through maturity in 2008 are $156,313 in 2007 and $1,516,504 in 2008.

7. Series 2006-A Convertible Preferred Stock

On June 8, 2006, the Company completed a private placement of $2,150,000 with 10 institutional and accredited investors pursuant to the 2006 Series A Convertible Preferred Stock Agreement dated June 7, 2006. Net proceeds from the placement were approximately $1,969,000. The Company issued 2,150 shares of Series 2006-A Convertible Preferred Stock, par value $0.001 per share (the “Convertible Preferred Stock”), at a purchase price of $1,000 per share. Each investor also received a Series A Warrant (a “Warrant”) to purchase up to 75% of the number of shares of common stock issuable to him upon conversion of his Convertible Preferred Stock. If all of the Warrants are exercised, the Company will issue a total of 2,015,625 shares of common stock. In addition, the Company issued to the placement agent 631,562 warrants valued at $645,881 and paid fees of $181,000. All the warrants have a term of 5 years and the initial exercise price of $1.50 per share has been adjusted to $1.00 per share as the contingent event stated in the agreement failed to materialize. This $1.00 exercise price is subject to adjustments for certain corporate events such as merger, reorganization or future sale of securities at a price below the exercise price. As the fair value of warrants and conversion option exceeded the net proceeds of $2,150,000 from preferred stock, the Company deemed the fair value of the preferred stock to be $0 at inception. The $2 reflects the minimum par value of the stock.

The Convertible Preferred Stock is convertible to shares of common stock at an initial conversion price of $0.80 per share, which has been since adjusted to $0.50 per share, as the contingent event stated in the agreement failed to materialize. The conversion price of $0.50 per share is subject to adjustment in the event of certain corporate events such as merger, reorganization or future sale of securities at a price below the conversion rate. Cash dividends accrue on the Convertible Preferred Stock at the rate of 8% per annum, payable quarterly beginning in October 2006; or, at the Company's option, dividends are payable in shares of the Company’s common stock, accruing at the rate of 10% per annum based on the volume-weighted average market price for shares of common stock for the 10 trading days preceding payment. In January 2007, a dividend was paid on the Company’s 2006 Series A Convertible Preferred Stock with 81,068 shares of the Company’s common stock valued at $49,500.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

As of March 31, 2007, the Company has accrued $49,500 in dividends at the rate of 10% per annum. In April 2007, subsequent to the balance sheet date, this dividend was paid with 85,095 shares of the Company’s common stock.

The Company may mandate conversion of the Convertible Preferred Stock if the closing bid price of the common stock exceeds $2.50 for twenty (20) consecutive trading days. In the event of a merger or sale of more than 50% of the assets of the Company, or in the event shares of common stock issuable upon the conversion of Convertible Preferred Stock or exercise of warrants fail or cease to be registered as contemplated by the terms of the Certificate of Designation of the Relative Rights and Preferences of Series 2006 A Convertible Preferred Stock, the Convertible Preferred Stock is redeemable at a price of $1,000 per share, plus any accrued and unpaid dividends payable thereon, payable at the option of the Company in cash or in shares of the Company’s common stock.

In connection with the issuance of the Preferred Stock and Warrants pursuant to the June 8, 2006 private placement described above, we agreed to file a registration statement with the Securities and Exchange Commission to register for sale the shares of common stock issuable upon conversion of Convertible Preferred Stock and the exercise of Warrants. The Company was required to file a registration statement on or before August 4, 2006, which was timely filed. If the registration statement is not timely declared effective or is suspended for a certain length of time, the Company is required to pay 1% of the purchase price of the Convertible Preferred Stock for each 30 day period or portion thereof after such effective date until the registration statement is declared effective or reinstated.

There is no stated limit on the maximum penalty that could be incurred. However, the maximum penalty is effectively capped as the period or periods for which payments are due for events of default and limited under the registration rights agreement to 24 months. Accordingly, the penalty is capped at 24%.

The Company is required to keep the Registration Statement continuously effective until such date as is the earlier of (x) the date when all Registerable Shares covered by the registration statement have been sold or (y) the date on which the Registerable Shares may be sold without any restriction pursuant to Rule 144 as determined by Counsel to the Company. The registration statement was timely filed and declared effective. On October 13, 2006, the Company announced its intention to restate financial statements, and suspended use of its Registration Statement declared effective by the SEC October 4, 2006. For such time as the Registration Statement is not effective, the Company is obligated, pursuant to Company’s Registration Rights Agreement with holders of the Company’s Convertible Preferred Stock, to pay such holders an amount equal to one percent per month of the original purchase price of the Convertible Preferred Stock until the earlier of the date the Registration Statement is again declared effective by the SEC, or June 2008. As of March 31, 2007, a penalty of $64,500 was accrued for the first quarter 2007 and $100,200 in cumulative penalties has been accrued since the registration was suspended.

The Company has accounted for the conversion option in the preferred stock as an embedded derivative under the provisions of FAS 133: Accounting for Derivative Instruments and Hedging Activities. Pursuant to the provisions of Statement of Financial Accounting Standards No. 133, and EITF 00-19: “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock” (“EITF 00-19”), the Company had initially recorded the value of the warrants and conversion option at $2,095,930 and $3,698,316, respectively which are reflected as derivative instruments on the balance sheet. As the proceeds from the issuance of preferred shares of $2,150,000 were less than the combined fair value of the warrants and the conversion option, the initial difference of $3,644,246 was charged to financing costs, a non-operating expense, in the statements of operations.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

At inception, the Warrants and Conversion Options had a reset provision for the exercise price based on the same contingent event. Management assigned an equal probability of 50% to each of the conditions at inception to weight the fair value. The Company computed the weighted fair value at June 8, 2006 of the Series A Warrants and Conversion Options using the Black-Scholes pricing model with the following weighted average assumptions:

Stock price	$1.10
Exercise price	$0.5-1.5
Expected life in years	4.5 years
Risk free interest rate	5.04%
Expected volatility	179%
Dividend yield	0%

As of March 31, 2007, the Company believed that none of the events that trigger redemption upon major corporate events were probable of occurring. The Company believes that many of these events are within its control and accordingly the probability of occurrence of any of such events is small. Other events that are not within the Company’s control and which trigger redemption are lapse of registration or unavailability of registration and suspension of listing. The Company believes that although these events are not in its control, as of March 31, 2007, redemption was not likely and that the Company could cure within any cure period after receipt of a Notice of Redemption. As such, in accordance with paragraphs 15 of EITF Topic D-98: Classification and Measurement of Redeemable Securities, the Preferred Stock is not currently accreted to its redemption value and there is no likelihood that it will become redeemable; accordingly, no accretion is being made to bring the carrying value up to its redemption value.

As of March 31, 2007, the liability for the value of the warrants and conversion option was “marked to market” and the difference of $562,596 and $833,665, respectively, has been accounted for as a decrease to the derivative expense initially recognized in the statements of operations. The liability for the value of the conversion option and warrants will be “marked to market” in future accounting periods until such time as the preferred shares are converted and the warrants are exercised or they meet the criteria for equity classification. As of March 31, 2007, the Company used the Black-Scholes option pricing model to revalue the fair value of warrants and conversion options with the following assumptions:

Stock price	$0.35
Exercise price	$0.5-1.0
Expected life in years	4.17 years
Risk free interest rate	4.54%
Expected volatility	136.8%
Dividend yield	0%

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

8. Shareholders’ Equity Transactions

During the period ended March 31, 2007, the Company issued 81,068 shares of common stock for payment of accrued dividends in the amount of $49,500.

As of March 31, 2007, the Company has accrued $49,500 in dividend obligations at the rate of 10% per annum. In April 2007, subsequent to the balance sheet date, this dividend was paid with 85,095 shares of the Company’s common stock.

9. Stock-Based Compensation Plans

Plan Options

The Company has two stock option plans, a "1992 Plan", under which 350,000 shares of its common stock have been reserved for issuance, and a "1994 Plan", under which an additional 350,000 shares of its common stock have been reserved for issuance. Under both plans, the Company's Board of Directors may grant either incentive stock options with an exercise price of not less than the fair market value of the common stock at the date of grant or non-qualified stock options with an exercise price of not less than 85% of the fair market value of the common stock at the date of grant. The Board of Directors shall determine the period of each option and the time or times at which options may be exercised and any restrictions on the transfer of stock issued upon exercise of any options. Both plans also provide for certain automatic grants to each non-employee director at a price of 100% of fair market value of the common stock at the time of grant. Options generally vest over a period of six months and are exercisable over a period of five years.

Non-Plan Options

Method of Accounting

On March 25, 2005, 550,000 stock options were granted to one employee and on May 2, 2005, another 550,000 stock options were granted to a second employee in accordance with their employment agreements. Both employment agreements provided for immediate vesting of 100,000 stock options at an exercise price of $0.10 on date of grant and then vesting of the remaining 450,000 stock options in three equal tranches of 150,000 stock options on October 1, 2005, October 1, 2006 and October 1, 2007, at an exercise price of $1.00 per share. These options are exercisable until June 1, 2015. During the periods ended March 31, 2007 and 2006, the Company recorded $60,924 and $164,614 respectively as compensation expense.

The fair value for stock awards was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	2006
Expected term (in years)	5
Expected stock price volatility	206%
Risk-free interest rate	4.27%
Expected dividend yield	0%
Estimated fair value per option granted	2.25

Effective January 1, 2006, the Company’s Plan and options granted outside of the Plan are accounted for in accordance with the recognition and measurement provisions of Statement of Financial Accounting Standards ("FAS") No. 123 (revised 2004), Share-Based Payment ("FAS 123(R)"), which replaces FAS No. 123, Accounting for Stock-Based Compensation, and supersedes Accounting Principles Board Opinion ("APB") No. 25, Accounting for Stock Issued to Employees, and related interpretations. FAS 123 (R) requires compensation costs related to share-based payment transactions, including employee stock options, to be recognized in the financial statements. In addition, the Company adheres to the guidance set forth within Securities and Exchange Commission ("SEC") Staff Accounting Bulletin ("SAB") No. 107, which provides the Staff's views regarding the interaction between FAS No. 123(R) and certain SEC rules and regulations and provides interpretations with respect to the valuation of share-based payments for public companies.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

In adopting FAS 123(R), the Company applied the modified prospective approach to transition. Under the modified prospective approach, the provisions of FAS 123(R) are to be applied to new awards and to outstanding awards modified, repurchased, or cancelled after the required effective date. Additionally, compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the required effective date shall be recognized as the requisite service is rendered on or after the required effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated for either recognition or pro-forma disclosures under FAS 123.

Prior to January 1, 2006, the Company accounted for similar transactions using APB 25 and FASB Interpretation No. 28, Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans, an interpretation of APB Opinions No. 15 and No. 25 (“FIN 28”). The Interpretation clarifies the accounting for compensation related to variable stock options and specifies that compensation should be measured at the end of each period as the amount by which the quoted market value of the shares of the Company’s common stock covered by a grant, exceeds the option price or value specified under the plan and should be accrued as a charge to expense over the periods the employee performs the related services. Changes in the quoted market value should be reflected as an adjustment of accrued compensation and compensation expense in the periods in which the changes occur until the date the number of shares and purchase price, if any, are both known.

In January 2006, the Company granted options to its two outside directors, Richard Woodrich and Joseph Levi, to purchase in the aggregate 100,000 shares of Company's common stock. The options vest quarterly in equal amounts over a period of three years, and are exercisable for seven years from the vesting date at an exercise price of $1.00.

The Company's results for the three months ended March 31, 2007 include share-based compensation expense of $11,622 recorded in the selling, general and administrative expenses.

Stock option compensation expense in fiscal 2006 is the estimated fair value of options granted amortized on a straight-line basis over the requisite service period for the entire portion of the award. The Company has not adjusted the expense by estimated forfeitures, as required by FAS 123(R) for employee options, since the forfeiture rate based upon historical data was determined to be immaterial.

The fair value for stock awards was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:


Expected term (in years)	5
Expected stock price volatility	182%
Risk-free interest rate	4.35%
Expected dividend yield	0%
Estimated fair value per option granted	1.395

The following table summarizes all stock option activity for options granted under the 1992 Plan, the 1994 Plan and non-plan options during the three months ended March 31, 2007:

	Number of Options		Weighted Average Exercise Price
Outstanding at January 1, 2007		1,200,000	$	0.85
Granted		--
Exercised		--
Forfeited/expired		--
Outstanding at March 31, 2007		1,200,000	$	0.85
Exercisable at March 31, 2007		833,333	$	0.42

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

As of March 31, 2007, there was $126,157 of unrecognized compensation cost related to non-vested awards granted, which is expected to be recognized over a weighted-average period of less than a year. The following table summarizes the information about stock options outstanding at March 31, 2007:

Options Outstanding				Options Exercisable
Range of Exercise Price Per Share	Number Outstanding at March 31, 2007	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price Per Share	Number Exercisable at March 31, 2007	Weighted Average Exercise Price Per Share
$0. 10-$1.00	1,200,000	7.93	$ 0.85	833,333	$0.42

The following table summarizes the information about warrants outstanding at March 31, 2007:

	Number of Warrants		Weighted Average Exercise Price
Outstanding at January 1, 2007		2,707,187	$	0.98
Granted		-
Exercised		-
Forfeited/expired		-
Outstanding at March 31, 2007		2,707,187	$	0.98

Of the above warrants, 60,000 expire in 2007, and 2,647,187 expire in 2011.

10. Contingencies

EMPLOYMENT CONTRACTS

In March and May of 2005, the Company entered into employment agreements respectively with Steve Peltzman, Chief Executive Officer and Chairman of the Board, and Bruce Pattison, President. Both agreements provide a minimum annual base salary of $120,000 for a term of two years and renewable annually. Either party can terminate the agreement upon 90 days notice. This base salary will increase to $180,000 per year upon closing of a financing to the Company with minimum gross proceeds of $3,000,000. The Company is also obligated to pay health and life insurance benefits and reimburse expenses incurred by the officers on behalf of the company. Each executive, if terminated by the Company without cause, would be entitled to six months severance.

ECONOMIC DEPENDENCY

For the three months ended March 31, 2007, sales to two customers were in excess of 10% of the Company's total sales. Sales to these customers were approximately $70,000 and $52,000 and accounts receivable from these customers as of March 31, 2007, aggregated $81,000 and $0, respectively. The loss of either of these customers could have a material adverse effect on the Company. The Company is continuing to seek new markets and sales opportunities for its products.

For the three months ended March 31, 2007, purchases from three suppliers were in excess of 10% of the Company's total purchases. The purchases from these suppliers for the first quarter 2007 were $7,197, $8,955 and $10,968. The corresponding accounts payable to these suppliers were $0, $7,832 and $7,816.

CONTINGENT OBLIGATION TO PREFERRED STOCKHOLDERS

On October 13, 2006, the Company announced its intention to restate financial statements, and suspended use of its Registration Statement declared effective by the SEC October 4, 2006. For such time as the Registration Statement is not effective, the Company is obligated, pursuant to the Company’s Registration Rights Agreement with holders of the Company’s Convertible Preferred Stock, to pay such holders an amount equal to one percent per month of the original purchase price of the Convertible Preferred Stock until the earlier of the date the Registration Statement is again declared effective by the SEC, or June 2008.

STATSURE DIAGNOSTIC SYSTEMS, INC.

NOTES TO FIANCIAL STATEMENTS (UNAUDITED)

March 31, 2007

As a result of the suspension, the Company has accrued penalties through March 31, 2007 of $100,200. Such penalties continued to accrue at rate of $21,500 per month until May 11, 2007, when the Registration Statement was declared effective.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion of the Company's financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company's other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company's fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

GENERAL

StatSure Diagnostic Systems, Inc., (SDS), a Delaware corporation (the “Company” or “StatSure”), is primarily engaged in commercializing two product platforms: first, the development, manufacturing and marketing of oral-fluid collection devices to provide physiologic samples to screen for the presence of drugs-of-abuse or infectious diseases; second, the development of point-of-care (POC), rapid, immunoassays for use in the detection of infectious diseases. These immunoassays incorporate SDS’ patented “barrel” technology, designed to provide speed, safety and convenience which are considered critical factors in point-of-care markets. In the oral fluid collection market, the Company’s platform has a patented internal quality control that indicates sufficient volume of the oral fluid sample (“volume adequacy indicator”).

The Company's principal executive offices are located at 1 Clarks Hill, Framingham, MA. 01702.

On September 29, 2006, the Company announced it had signed several agreements relating to its patented barrel technology for use in screening antibodies to HIV (Human Immunodeficiency Virus, the virus that causes AIDS). As part of a three-way alliance with Inverness Medical Innovations (AMEX:IMA) and Chembio Diagnostics (CEMI.OB) (“Chembio”), StatSure signed a worldwide, exclusive distribution deal for a rapid, point-of-care HIV test with Inverness. In a two-way deal with Chembio, the Company granted an exclusive license to Chembio solely to manufacture their recently FDA approved HIV barrel product for Inverness Medical Innovations (“IMA” or “Inverness”). This product will be marketed under the IMA brand. In this two-way agreement (“Joint HIV Barrel Commercialization Agreement”), a long- term strategic “partnership” was established, wherein both companies equally split the margin dollars of the HIV barrel product once the actual cost of manufacturing is reimbursed.

The Company and Chembio also entered into a Settlement Agreement pursuant to which all matters in their litigation regarding StatSure’s barrel patent and other matters were settled. As previously stated, under the terms of this agreement, the parties will equally share in the profits relating to CLEARVIEW COMPLETE HIV1/2 (the IMA brand-name for the HIV barrel-based) product after reimbursement of the manufacturing and related costs, as defined, and the parties will act jointly in the HIV barrel field. The Settlement combines each company’s HIV barrel intellectual property, including an exclusive manufacturing license from StatSure to Chembio of its barrel patent for all HIV applications, thereby ensuring their exclusive right to manufacture, as well as Inverness’ right to market and distribute though the marketing license that StatSure granted Inverness under the three way agreement.

On February 14, 2007, Inverness introduced the licensed HIV barrel-based product (CLEARVIEW® Complete HIV 1/2) to its U.S. Sales force. Inverness/Chembio is in the process of filing for a waiver of CLIA for the licensed barrel HIV product, which if received, will allow sales of this product to a large number of markets that do not operate under the standards of the CLIA (e.g. doctors' offices, public health clinics). If it is not obtained, marketing and sales of the product will be restricted to those laboratory settings with CLIA certification, which will seriously restrict the revenues derived from the product. The submission of an application to the FDA or other regulatory authority for these or other claims does not guarantee that an approval or clearance to market the product will be received.

The Company has incurred significant operating losses since its inception, resulting in an accumulated deficit of $50,895,142 at March 31, 2007. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. The Company's independent certified public accountants have included an explanatory paragraph in their report on the Company’s Form 10-KSB for December 31, 2006 stating that the Company's significant operating losses and significant capital requirements raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to continue its business, or that such financing will be available on commercially reasonable terms or at all. (See note 2 of notes to financial statements.)

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the unaudited Financial Statements and accompanying notes. Estimates are used for, but not limited to, the accounting for the allowance for doubtful accounts, inventories, income taxes and loss contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. (SEE CRITICAL ACCOUNTING POLICIES - FORM 10-KSB FOR THE YEAR ENDED DECEMBER 31, 2006)

RESULTS OF OPERATIONS

First Quarter of 2007 Compared to First Quarter of 2006

REVENUES: The Company’s revenues consist of product sales, royalties and other income. Revenues decreased to $153,848 in the first quarter of 2007 from the revenues of the first quarter of 2006 of $213,059. The 2007 decrease in revenues was due to fewer sales of our saliva collector. The Company's revenues are primarily generated from sales of its patented saliva collection devices. Specimens collected with the device are sent to and processed at laboratories. The Company expects an increase in revenues in the second quarter 2007 over the second quarter 2006.

In 2007, rental income of $10,986 was received from Chembio Diagnostic Systems, Inc., for the use of an assembly machine.

COST OF PRODUCTS SOLD: Costs of products sold decreased to $21,729 (15% of product sales) in the first quarter of 2007 from $46,390 (22% of product sales) in the first quarter of 2006.

RESEARCH AND DEVELOPMENT EXPENSES: Research and development expenses decreased to $21,048 in the first quarter of 2007 from $69,149 in the first quarter of 2006. The decrease in the first quarter 2007 is due to the abandonment of the StatSure(TM) HIV test clinical trials in the fourth quarter of 2006. The expenses for research and development are expected to continue decreasing until such time as the Company has sufficient funds to implement a new R&D program.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses decreased to $431,104 in the first quarter of 2007, from $661,340 in the first quarter of 2006. During the first quarter of 2007 the Company had a decrease in payroll expenses of approximately $100,000 due to payment through equity issuances in 2006, and a decrease in consulting expense of $134,000 paid with equity issuances in 2006.

INTEREST EXPENSE, NET: Interest expense, net decreased to $55,034 in 2007 from $123,962 in 2006. The decrease in 2007 was due to lower principal balances on debentures and notes payables to shareholders which resulted in lower interest expense.

INTEREST EXPENSE ON BENEFICIAL CONVERSION FEATURE: Interest expense on beneficial conversion feature decreased to $36,310 in the first quarter of 2007 from $117,612 in the first quarter of 2006. The decrease of this non-cash expense was due to the conversion of $400,000 of debentures which resulted in the related beneficial conversion being written off.

DERIVATIVE INCOME: Non-cash derivative income of $1,396,261 for the three months ended March 31, 2007 was due to the mark-to market adjustment on embedded derivatives principally driven by the decrease in our common stock price $0.55 to $0.35. The Company did not have derivative instruments in the same period of 2006.

PENALTIES: As a result of the withdrawal of the registration statement filed in 2006, the Company accrued penalties of $64,500 for the first quarter of 2007, to the holders of the 2006 Series A Convertible Preferred Stock. Such penalties continued to accrue at rate of $21,500 per month until May 11, 2007, when the Registration Statement was declared effective.

LIQUIDITY AND CAPITAL RESOURCES

	March 31, 2007		December 31, 2006
Cash and cash equivalents	$	24,837	$	109,332
Working capital deficit		902,034		659,517

Net cash used by operating activities in the first quarter 2007 was $149,698 compared to $88,270 used during the same period 2006. In 2007, the increase in cash used by operations was primarily due to the net effect of net income of $920,384 in 2007, and a net loss of ($805,394) in 2006 combined with the mark-to-market gain on derivative instruments of $1,396,261 in 2007.

Cash used in investing activities in the first quarter 2007 was $6,110 as compared to $34,814 in the first quarter 2006. The 2006 amount includes $34,814 additions to patents and trademarks. The Company incurred less costs in 2007.

Cash provided by financing activities in the first quarter 2007 was $71,313 compared to $56,370 for the first quarter 2006. During 2007 the Company received $71,313 of net proceeds from a shareholder loan, compared to $41,370 in 2006.

As of March 31, 2007 there are outstanding $337,500 of 9% Convertible Debentures due in January 2009. Holders of the 9% Convertible Debentures are entitled to convert principal amounts into shares of common stock at a conversion price of $1.00. The Company is in default to these debenture holders for not making payments on a timely basis. As a result, in accordance with the debenture agreements, these debentures became payable on demand unless the default is waived by the investors. The amount of debentures at March 31, 2007 of $337,500 plus accrued interest of $23,476 has therefore been reflected as a current liability. The Company has not received any notice of default from any of the holders of the outstanding debentures. Debentures payable-net of discount in the amount of $106,878, is the net of gross amount of debenture payables of $337,500 reduced by unamortized debt discount of $230,622, and is shown on the balance sheet as a current liability.

The following table lists the future payments required on debt and any other contractual obligations of the Company as of March 31, 2007.

Obligations	Total		Less than 1 year		1-3 years

Long-term debt	$	1,779,695	$	263,191	$	1,516,504
Operating leases		66,226		56,220		10,006

The Company occupies premises in Framingham, MA. The lease has a three-year initial term ending March 31, 2008 and a base annual rental rate starting at approximately $26,350 and increasing to approximately $40,500 per year over that initial term. The lease also has a one-year renewal option at an annual base rental rate of approximately $40,500. The Company also occupies premises in Brooklyn, New York. The lease has a three-year term ending August 30, 2008 and a base annual rental rate starting at $15,000 and increasing to $15,913 per year.

Since inception, the Company has financed its capital requirements through the proceeds from its public offering of common stock in March 1993 and the exercise of common stock purchase warrants pursuant to such offering, proceeds from sales of convertible debentures, proceeds from private placements of common stock and preferred stock, the exercise of common stock purchase warrants and stock options and loans.

There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement or continue its programs, or that such financing will be available on commercially reasonable terms or at all. The Company will continue to seek public or private placement of its equity securities and corporate partners to develop products. There can be no assurance that the Company will be able to sell its securities on commercially reasonable terms or to enter into agreements with corporate partners on favorable terms or at all. The Company's future capital needs will depend upon numerous factors, including the progress of the approval for sale of the Company's products in various countries, including the U.S., the extent and timing of the acceptance of the Company's products, the cost of marketing and manufacturing activities and the amount of revenues generated from operations, none of which can be predicted with certainty. The Company's significant operating losses and capital requirements raise substantial doubt about the Company's ability to continue as a going concern.

OFF-BALANCE SHEET ARRANGEMENTS. The Company does not have any off-balance sheet arrangements, as defined in Item 304(a)(4)(ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we evaluated, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, the effectiveness of the design and operation of our "disclosure controls and procedures" [as defined in the Securities Exchange Act of 1934, Rules 13a - 15(e) and 15d - 15(e)]. It should be noted that the Company had amended its 2005 Forms 10Q-SB (March 31, June 30, and September 30), 10-KSB and 2006 Form 10-QSB for the quarters ended March 31, 2006, June 30, 2006 and September 31, 2006 filings with the SEC. The reason for the amended filing was due to complex financial transactions which resulted in accounting restatements in response to an SEC routine inquiry. As a result, our chief executive officer and chief financial officer have concluded that as of December 31, 2005 our disclosure controls and procedures were not sufficiently effective to ensure that all material information required to be filed in those reports had been made known to them. Subsequent thereto, we have engaged an accounting firm other than our auditors to assist in the accounting for these complex transactions. Management believes that these additional procedures and measures ensure that proper disclosure controls and procedures are in place and that all material information required to be filed in those reports.

CHANGE IN INTERNAL CONTROLS

There have been no changes in internal controls over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

On January 9, 2007, as payment of dividends on the Company’s Series 2006-A Convertible Preferred Stock, the Company issued 81,068 shares of common stock to holders of the Series 2006-A preferred stock. No cash was exchanged in this issuance. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The investors in the issuance were accredited investors of the Company.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

The Company has defaulted on a total of $355,366 of convertible debentures. The amount of principal payments in arrears was $337,500, with an additional amount of $17,866 of interest due at March 31, 2007. These defaults are the result of a failure to pay in accordance with the terms agreed.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibit index

Exhibit

31.1	Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2	Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1	Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K:

Date	Items Reported

2/16/07	99.1

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 21, 2007


	STATSURE DIAGNOSTIC SYSTEMS, INC.

	By:	/s/ Steve M. Peltzman
		Steve M. Peltzman
		Chief Executive Officer (principal executive officer)


	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Chief Financial Officer (principal financial officer)